Skip to main content

Market Overview

Trovagene to Present at the 19th Annual Needham Healthcare Conference


SAN DIEGO, April 8, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including colorectal, prostate and leukemia, today announced it will be presenting at the 19th Annual Needham Healthcare Conference at 3:30 p.m. Eastern time on Wednesday, April 15, 2020. The conference is being held on Tuesday and Wednesday, April 14 and 15, in a virtual format.

Dr. Thomas Adams, Chief Executive Officer and Chairman, and Dr. Mark Erlander, Chief Scientific Officer, of Trovagene, will provide an overview of the Company's business and advancing clinical development programs for its investigational drug, onvansertib, during the live presentation. They will also be conducting one-on-one calls with investors throughout the conference.

The presentation will be webcast live and available for replay on Trovagene's website by clicking here. The webcast replay will remain available for 90 days following the live presentation.

About Trovagene, Inc.

Trovagene is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.  Our goal is to overcome resistance, improve response to treatment and increase overall survival.  We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.  Three clinical programs are advancing and demonstrating the safety and efficacy of onvansertib: Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin in KRAS-mutated metastatic colorectal cancer (mCRC); Phase 2 study of onvansertib in combination with Zytiga® (abiraterone)/prednisone in Zytiga-resistant metastatic castration-resistant prostate cancer (mCRPC); and Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML). For more information, please visit

Trovagene Contact:
Vicki Kelemen
VP, Clinical Development and Investor Relations

Cision View original content to download multimedia:

SOURCE Trovagene, Inc.

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at